High Testosterone in Women: What Could Be Causing It

Why Testosterone Rises in Women

Testosterone in women originates from three sources: the ovaries (25%), the adrenal glands (25%), and peripheral conversion of precursors like DHEA-S and androstenedione in fat and skin tissue (50%). Any disruption across these sites can push androgen levels above the reference range of approximately 15-70 ng/dL for total testosterone.

The hypothalamic-pituitary-ovarian axis regulates testosterone production through luteinizing hormone (LH). When LH pulse frequency increases, ovarian theca cells produce excess androgens. This mechanism drives the majority of PCOS-related hyperandrogenism. Separately, adrenocorticotropic hormone (ACTH) stimulates adrenal androgen output. Disruption at either level, or both simultaneously, produces measurable clinical effects.

Peripheral conversion matters more than most patients realize. Adipose tissue contains the enzyme aromatase, but it also harbors 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT). A woman with normal ovarian and adrenal function but significant visceral adiposity may still develop androgen-excess symptoms through this peripheral pathway alone.

Polycystic Ovary Syndrome: The Leading Cause

PCOS is responsible for the vast majority of high testosterone presentations in premenopausal women. The Rotterdam criteria require two of three features: oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. A 2023 international evidence-based guideline endorsed by the Endocrine Society confirmed these diagnostic standards while emphasizing that ultrasound is not required for diagnosis in adolescents.

Testosterone levels in PCOS typically range from mildly to moderately elevated. Total testosterone between 70-150 ng/dL with an elevated free testosterone fraction represents the most common biochemical pattern. Values exceeding 200 ng/dL should prompt investigation for non-PCOS causes, particularly androgen-secreting tumors.

The metabolic component of PCOS deserves attention. Insulin resistance amplifies ovarian androgen production by stimulating theca cells directly and by suppressing hepatic sex hormone-binding globulin (SHBG) synthesis. Lower SHBG means more bioavailable testosterone. A 2020 meta-analysis involving over 35,000 women confirmed that insulin resistance is present in 50-70% of PCOS patients regardless of body mass index.

Adrenal Causes of Elevated Testosterone

Non-classic congenital adrenal hyperplasia (NCAH) due to 21-hydroxylase deficiency affects 1-10% of women presenting with hyperandrogenism, depending on ethnic background. It mimics PCOS clinically but has a distinct biochemical signature: an elevated 17-hydroxyprogesterone level, particularly when measured in the early follicular phase. The Endocrine Society clinical practice guideline recommends screening with an early-morning 17-OHP in all women with unexplained hyperandrogenism. A basal value exceeding 200 ng/dL warrants ACTH stimulation testing.

Cushing syndrome presents another adrenal pathway to hyperandrogenism. Chronic cortisol excess from pituitary adenomas, ectopic ACTH production, or exogenous glucocorticoid use drives adrenal androgen overproduction. The clinical presentation includes central obesity, purple striae, proximal muscle weakness, and easy bruising alongside androgen-excess symptoms. Screening involves 24-hour urinary free cortisol, late-night salivary cortisol, or the 1-mg overnight dexamethasone suppression test.

Adrenal tumors (adenomas and carcinomas) are rare but clinically significant. They produce rapid-onset virilization with testosterone levels frequently exceeding 200 ng/dL and DHEA-S levels above 700 mcg/dL. Adrenal carcinomas carry a poor prognosis, making early detection through cross-sectional imaging essential when biochemistry suggests an adrenal source.

Ovarian Tumors and Hyperthecosis

Androgen-secreting ovarian tumors account for fewer than 5% of hyperandrogenism cases but demand rapid identification. Sertoli-Leydig cell tumors, hilus cell tumors, and granulosa cell tumors can produce testosterone levels above 200 ng/dL with sudden-onset deepening voice, clitoromegaly, and temporal hair recession. These symptoms developing over weeks to months, rather than years, constitute a red flag.

Ovarian hyperthecosis differs from PCOS in degree rather than mechanism. Nests of luteinized theca cells in the ovarian stroma produce substantial androgens without forming discrete cysts. This condition is more common in postmenopausal women and typically causes testosterone levels between 100-200 ng/dL. Unlike PCOS, hyperthecosis responds poorly to combined oral contraceptives and may require GnRH agonist therapy or bilateral oophorectomy.

A 2019 systematic review of virilizing ovarian tumors in postmenopausal women found that transvaginal ultrasound detected the lesion in 78% of cases. When ultrasound is inconclusive, MRI with contrast or selective ovarian venous sampling may localize the androgen source.

Medications and Exogenous Sources

Several commonly prescribed medications raise testosterone in women. Valproic acid, used for epilepsy and bipolar disorder, increases androgen levels through multiple mechanisms including direct stimulation of ovarian steroidogenesis and weight gain-mediated insulin resistance. A study of 200 women on valproate found hyperandrogenism in 43%.

Testosterone replacement therapy, even at physiologic female doses, can overshoot target ranges. Compounded testosterone creams, pellets, and troches lack the standardized dosing of FDA-approved products, making supratherapeutic levels common. Transfer from a male partner using topical testosterone gel represents an underrecognized source. The FDA requires boxed warnings on testosterone gels regarding secondary exposure risk.

Other culprits include danazol (used for endometriosis), DHEA supplements available over the counter, anabolic steroids, and certain progestins with androgenic activity like levonorgestrel and norethindrone at high doses. A thorough medication and supplement history is non-negotiable during workup.

The Role of Insulin Resistance and Obesity

Insulin resistance operates as both a cause and amplifier of hyperandrogenism independent of PCOS diagnosis. Hyperinsulinemia directly stimulates ovarian theca cell androgen production via insulin and IGF-1 receptors. Simultaneously, insulin suppresses hepatic SHBG synthesis, increasing the bioavailable fraction of circulating testosterone. A landmark study by Nestler et al. demonstrated that reducing insulin with diazoxide decreased testosterone in obese women within days.

Visceral adiposity amplifies the problem through inflammatory cytokines (TNF-alpha, IL-6) that further impair insulin signaling and through local androgen conversion via 5-alpha reductase in adipose tissue. Weight loss of just 5-10% has been shown to reduce free testosterone by 20-30% in overweight women with PCOS.

The relationship is bidirectional. Excess androgens promote visceral fat deposition, creating a self-reinforcing cycle. Breaking this cycle through lifestyle intervention, metformin, or newer agents like GLP-1 receptor agonists represents a cornerstone of management.

Diagnostic Workup: Getting the Right Tests

The Endocrine Society recommends measuring total testosterone, free testosterone (by equilibrium dialysis or calculated from SHBG), and DHEA-S as the initial biochemical panel. Blood should be drawn fasting, in the early morning (before 10 AM), and between days 4-10 of the menstrual cycle if cycles are present.

Dr. Ricardo Azziz, a leading researcher in androgen excess disorders, has stated: "The single most important step in evaluating hyperandrogenism is obtaining accurate androgen measurements using reliable assays. Direct immunoassays for free testosterone are unreliable in women and should not be used."

Additional tests depend on clinical suspicion. A 17-hydroxyprogesterone screens for NCAH. A 24-hour urinary free cortisol or overnight dexamethasone suppression test evaluates for Cushing syndrome. Prolactin and TSH rule out other pituitary and thyroid contributors. Anti-Mullerian hormone (AMH) is elevated in PCOS and may support the diagnosis when ultrasound is unavailable.

Imaging follows biochemistry. Pelvic ultrasound evaluates ovarian morphology. CT or MRI of the adrenals is indicated when DHEA-S exceeds 700 mcg/dL or when rapid virilization suggests a tumor. These tests should be interpreted by an endocrinologist or reproductive endocrinologist familiar with androgen-excess disorders.

Treatment Approaches by Underlying Cause

For PCOS-related hyperandrogenism in women not seeking pregnancy, combined oral contraceptives (COCs) remain first-line therapy. The estrogen component raises SHBG and suppresses LH-driven ovarian androgen production. Pills containing anti-androgenic progestins like drospirenone or cyproterone acetate offer additional benefit. The 2023 international PCOS guideline recommends COCs as first-line pharmacotherapy for hirsutism and acne in PCOS.

Spironolactone at 50-200 mg daily provides direct androgen receptor blockade and inhibits 5-alpha reductase. A randomized trial of 80 women found that spironolactone 100 mg daily reduced hirsutism scores by 40% over 6 months. It requires reliable contraception due to teratogenic risk.

For insulin-resistant phenotypes, metformin (1500-2000 mg daily) reduces androgen levels through insulin-sensitizing effects. A Cochrane review confirmed metformin lowers testosterone in PCOS, though its effect on hirsutism is modest compared to COCs or spironolactone.

Lifestyle modification parallels pharmacotherapy. The 2023 PCOS guideline recommends structured exercise (150 minutes per week of moderate intensity) and dietary intervention targeting 5-10% weight loss as foundational treatment regardless of BMI category.

For NCAH, low-dose glucocorticoids (hydrocortisone 10-15 mg/day or dexamethasone 0.25-0.5 mg at bedtime) suppress ACTH-driven adrenal androgen excess. Treatment is indicated only for symptomatic patients, as NCAH does not carry the salt-wasting risk of classic CAH.

When Elevated Testosterone Becomes Urgent

Certain clinical patterns require same-week specialist referral. Rapid virilization (voice deepening, clitoromegaly, male-pattern baldness developing over weeks rather than months) suggests an androgen-secreting tumor. Total testosterone above 200 ng/dL or DHEA-S above 700 mcg/dL in this context mandates urgent imaging.

New-onset hyperandrogenism in a postmenopausal woman warrants immediate investigation. The differential shifts heavily toward ovarian hyperthecosis and ovarian tumors after menopause, as PCOS is a diagnosis of reproductive-age women. A retrospective cohort of 58 postmenopausal women with testosterone above 150 ng/dL found ovarian pathology in 62%.

Signs of Cushing syndrome (moon facies, buffalo hump, proximal weakness, osteoporotic fractures in premenopausal women) require cortisol evaluation before attributing hyperandrogenism to PCOS. Missed Cushing diagnosis carries significant morbidity from cardiovascular disease, diabetes, and immunosuppression.

The Endocrine Society notes: "Any woman with total testosterone consistently above 150 ng/dL should undergo imaging of the ovaries and adrenal glands, even in the absence of rapid virilization, as slow-growing tumors may produce gradual androgen excess."

Long-Term Health Implications

Chronic hyperandrogenism carries consequences beyond cosmetic symptoms. Women with untreated PCOS face a 2-4 fold increased risk of type 2 diabetes compared to age-matched controls. Cardiovascular risk markers (dyslipidemia, elevated C-reactive protein, increased carotid intima-media thickness) are consistently elevated in hyperandrogenic women, though whether this translates to increased hard cardiovascular events remains under investigation.

Endometrial cancer risk rises in anovulatory women due to unopposed estrogen exposure. The relative risk is 2.7-fold in women with PCOS. Regular withdrawal bleeds through progestins or COCs are protective.

Mental health effects deserve recognition. Depression and anxiety are 3-4 times more prevalent in women with hyperandrogenism compared to controls. A 2019 meta-analysis of 18 studies confirmed significantly higher depression scores in PCOS patients independent of BMI. Whether this relationship is mediated by androgens directly, by the psychosocial burden of symptoms like hirsutism, or by shared neuroendocrine pathways remains an active research question.

Fertility implications vary by cause. PCOS-related anovulation responds well to letrozole (first-line for ovulation induction per the 2023 guideline) or clomiphene citrate. Ovarian drilling and gonadotropin therapy serve as second-line options. For NCAH, glucocorticoid suppression often restores ovulation without additional intervention.